Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343771 | 1.00 | MEN1 (0.47) | MEN1KMT2AACP3UGT2B7ADRB2 | |
| SCHEMBL819047 | 1.00 | MEN1 (0.47) | MEN1KMT2AACP3UGT2B7ADRB2 | |
| SCHEMBL15943135 | 1.00 | MEN1 (0.47) | MEN1KMT2AACP3UGT2B7ADRB2 | |
| SCHEMBL27382952 | 0.98 | MEN1 (0.46) | MEN1KMT2AACP3UGT2B7ADRB2 | |
| Hydrochloric Acid SCHEMBL7753577 | 0.98 | SLC2A1 (0.48) | MEN1KMT2AACP3UGT2B7ADRB2 | |
| Hydrochloric Acid SCHEMBL27389833 | 0.98 | SLC2A1 (0.48) | MEN1KMT2AACP3UGT2B7ADRB2 | |
| Oxalic Acid SCHEMBL27380050 | 0.90 | MEN1 (0.49) | MEN1KMT2AACP3ADRB2ADRB1 | |
| Fumaric Acid SCHEMBL27299351 | 0.86 | ALDH1A1 (0.50) | MEN1KMT2AACP3ADRB2ADRB1 | |
| SCHEMBL28951519 | 0.84 | ACP3 (0.46) | ACP3ADRB2ADRB1ADRB3SLC2A1 | |
| SCHEMBL9331659 | 0.83 | UGT2B7 (0.56) | MEN1KMT2AUGT2B7ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119776301-A | Alcohol dehydrogenase, recombinant genetically engineered bacterium and application thereof in asymmetric reduction of potential chiral carbonyl compounds | 杭州文德阶生物科技有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-104402661-A | Economic and efficient method for asymmetric synthesis of R-configuration aromatic alcohol through copper salt catalysis | UNIV JIANGNAN | 2015-03-11 | — | — | CN | claimed |
| CN-104311393-A | Preparation method of R-1-(3-chlorphenyl) ethanol and ester thereof | WANG TONGJUN | 2015-01-28 | — | — | CN | claimed |
| US-20250188068-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-06-12 | — | — | US | disclosed |
| EP-4561561-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | Septerna, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119776301-A | Alcohol dehydrogenase, recombinant genetically engineered bacterium and application thereof in asymmetric reduction of potential chiral carbonyl compounds | 杭州文德阶生物科技有限公司 | 2025-04-08 | — | — | CN | disclosed |
| EP-4490150-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-01-15 | — | — | EP | disclosed |
| US-20240199612-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-06-20 | — | — | US | disclosed |
| US-11999717-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| CN-114728168-B | Triazole carbamate pyridylsulfonamides as LPA receptor antagonists and their use | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20110112118-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-05-12 | — | — | US | disclosed |
| US-7888366-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-02-15 | — | — | US | disclosed |
| EP-1765810-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | Decode Chemistry, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| CN-1894213-A | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | MERCK & CO INC (CA) | 2007-01-10 | — | — | CN | disclosed |
| US-7019022-B2 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | MERCK FROSST CANADA & CO. (CA) | 2006-03-28 | — | — | US | disclosed |
| WO-2005123724-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050288314-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | DECODE CHEMISTRY, INC. (US) | 2005-12-29 | — | — | US | disclosed |
| US-20050154044-A1 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | MERCK FROSST CANADA LTD. (CA) | 2005-07-14 | — | — | US | disclosed |
| CN-1034497-C | Process for the preparation of aromatic aminoalcohol derivatives useful for the treatment of diabetes and obesity | SANKYO CO (JP) | 1997-04-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112118-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | SMN1; SMN2, MUSK, MYO3B | MEN1 2282/4885KMT2A 91/4885ACP3 3962/4885 |
| US-20050288314-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | SMN1; SMN2, MUSK, MYO3B | MEN1 2282/4885KMT2A 91/4885ACP3 3962/4885 |
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | MEN1 468/4885KMT2A 2250/4885ACP3 259/4885 |
| US-11999717-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | LPAR3, LPAR1, LPAR2 | MEN1 4586/4885KMT2A 1878/4885ACP3 250/4885 |
| US-20250188068-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | LPAR1, LPAR2, LPAR3 | MEN1 3284/4885KMT2A 3794/4885ACP3 1203/4885 |
| US-20050154044-A1 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | PTGIR, PTGDR, PTGDR2 | MEN1 4580/4885KMT2A 4598/4885ACP3 3654/4885 |
| US-20240199612-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK4 | MEN1 1066/4885KMT2A 659/4885ACP3 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.